Aurobindo Pharma Ltd

Aurobindo Pharma Regulatory Approval

Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.

Aurobindo Pharma Acquisition Worth ₹9.47 Cr

Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.

Value

₹9.47 Cr

Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr

Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.

Value

₹9.50 Cr

Aurobindo Pharma Business Update

Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.

Aurobindo Pharma Earnings Call Transcript: Key Takeaways

Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.

Call

Guides 10% growth

Aurobindo Pharma Investor Presentation: Key Takeaways

Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.

Aurobindo Pharma Q1 FY27 Results: Net Profit ₹1,032 Cr, Up 25.2% YoY

Aurobindo Pharma Ltd reported revenue from operations of ₹9,150 Cr (+16.3% YoY) and net profit of ₹1,032 Cr (+25.2% YoY) for Q1 FY27.

Key figure

Net profit ₹1,032 Cr · +25.2% YoY